Hacettepe University Faculty of Physical Therapy and Rehabilitation
Ankara, 06100, Turkey (Türkiye)
Location status: Recruiting
NCT Number: NCT06975982
Esophageal atresia is the most common congenital anomaly of the esophagus and is caused by abnormal development of the esophagus during intrauterine life. In children with esophageal atresia, structural abnormalities due to congenital anomalies and tracheoesophageal fistula, tracheomalacia, respiratory problems, recurrent respiratory tract infections, structural abnormalities, surgical interventions for repair and treatment, and decreased physical activity levels may negatively affect pulmonary function, effective coughing, muscle strength, exercise capacity, posture, motor function, and quality of life. This study aims to compare physical characteristics, body composition, pulmonary function and muscle strength, peak cough flow, posture assessment, peripheral muscle strength test, motor function, exercise capacity, physical activity level, fatigue, frailty and quality of life between children with esophageal atresia and their healthy peers.
Interested in participating?
Request Info6 year–18 year
All sexes
Observational
Ankara, 06100, Turkey (Türkiye)
Location status: Recruiting
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Esophageal atresia group
Inclusion criteria
Exclusion criteria
Control group
Inclusion criteria
Exclusion criteria
No intervention
Time frame: 1st day
Pulmonary function test using a spirometer will be performed. Forced vital capacity will be recorded.
Time frame: 1st day
Pulmonary function test using a spirometer will be performed. Forced expiratory volume in one second will be recorded.
Time frame: 1st day
Pulmonary function test using a spirometer will be performed. Forced expiratory volume in one second/forced vital capacity ratio will be recorded.
Time frame: 1st day
Pulmonary function test using a spirometer will be performed. Peak expiratory flow will be recorded.
Time frame: 1st day
Pulmonary function test using a spirometer will be performed. Forced mid-expiratory flow (FEF25-75) will be recorded.
Time frame: 1st day
Body composition will be evaluated by triceps skinfold thickness. Skinfold caliper will be used to evaluate triceps skinfold thickness.
Time frame: 1st day
Maximal inspiratory pressure will be measured using an mouthpiece pressure measuring device.
Time frame: 1st day
Maximal expiratory pressure will be measured using an mouthpiece pressure measuring device.
Time frame: 1st day
Peak cough flow will be measured using a peak flow meter.
Time frame: 1st day
Hand grip strength will be evaluated with a hand dynamometer device.
Time frame: 1st day
Knee extensor muscle strength will be assessed with a portable digital dynamometer.
Time frame: 1st day
Shoulder abductor muscle strength will be assessed with a portable digital dynamometer.
Time frame: 1st day
Motor function will be assessed using Time Up and Go test. In the Time Up and Go test, the individual is asked to stand up from a standard chair with armrests, walk 3 m, turn, walk back to the chair, and sit down again. The time is recorded in seconds.
Time frame: 1st day
6 minute walk test will be performed to assess functional capacity.
Time frame: 1st day
The Physical Activity Questionnaire for Children (PAQ-C) and the Physical Activity Questionnaire for Adolescents (PAQ-A) will be used to assess physical activity levels. The Turkish versions of these assessment tools have been shown to be valid and reliable. The total score ranges from 1 to 5, where 1 indicates very low physical activity, 5 indicates very high physical activity levels.
Time frame: 1 week after other assessments
To assess exercise capacity, a symptom-limited cardiopulmonary exercise test will be performed on a bicycle ergometer using Bruce protocol.
Time frame: 1st day
Frailty level will be calculated using the Composite Frailty Score: (1) Slowness: 6 minute walk test, (2) Weakness: handgrip strength, (3) Fatigue: Pediatric Quality of Life (PedsQL) Multidimensional Fatigue Scale (PedsQL-MFS), (4) Body composition: triceps skinfold thickness, and (5) Physical activity questionnaire. Each domain is scored on a 0-5 point scale, using z-scores or raw questionnaire scores to assign frailty points (0 = least frail, 5 = most frail). The five domain scores is summed to generate a Composite Frailty Score ranging from 0 to 25, where higher scores reflect greater frailty.
Time frame: 1st day
Quality of life will be assessed using Esophageal-Atresia-Quality of Life (EA-QOL) questionnaire. The EA-QOL questionnaire consist of a 17-item parent-reported questionnaire for children aged 2-7 years (eating, physical health and treatment, social isolation, and stress) and a 24-item questionnaire available as child- and parent-reported versions for children aged 8-17 years (eating, social relationships, body image, and health and well-being). Scores range from 0 to 100. Higher scores indicate better quality of life.
Time frame: 1st day
Fatigue will be assessed using the Pediatric Quality of Life Multidimensional Fatigue Scale (PedsQL-MFS). The PedsQL-MFS allows the child to assess their own fatigue and parents to assess their child's fatigue. The higher the score, the better the quality of life, indicating fewer fatigue symptoms. Therefore, a score of "0" on the PedsQL-MFS indicates greater fatigue, while a score of "100" indicates less fatigue.
Time frame: 1st day
Corbin Posture Rating Scale and observational posture analysis. It is an assessment consisting of lateral and posterior posture analysis. '0' is excellent, 12 and above indicates poor posture.
Contact information is provided by the study sponsor or research team.
Hacettepe University
Other
Comparison of Symptoms, Pulmonary Function, Muscle Strength, Exercise Capacity, and Frailty Level in Individuals With Esophageal Atresia and Healthy Individuals
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07100379
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Boston, Massachusetts, United States
View Trial DetailsNCT05995171
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Lille, Nord, France
View Trial DetailsNCT06860919
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Paris, France
View Trial DetailsNCT02883725
Congenital Abnormalities, Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Saint-Denis, La Réunion, France
View Trial Details